A Phase 3 interventional study of dimethyl fumarate in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Completed at 12 sites in 10 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-11-22.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 16th largest by enrollment, is one of 3 that started in 2016, is one of 10 in phase 3, and was the 17th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2016.
This study's enrollment of 20 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 48th largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2016, is one of 25 in phase 3, and was the 57th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200). Secondary objectives are as follows: To evaluate the long-term efficacy of BG00012 and to describe the long-term Multiple Sclerosis (MS) outcomes in subjects who completed Study 109MS202 (NCT02410200).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 120 mg capsule(s) taken orally.
Drug: dimethyl fumarate
administered orally
Also known as: DMF, BG00012
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence that does not necessarily have a causal relationship with treatment. An SAE is any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.
Time frame: Baseline to Week 96
Number of Participants Discontinuing Treatment Due to an Adverse Event
An AE is any untoward medical occurrence that does not necessarily have a causal relationship with treatment.
Time frame: Baseline to Week 96
Total Number of New or Newly Enlarging T2 Hyperintense Lesions From Week 16 to Week 24
T2 hyperintense lesions were measured by MRI brain scans.
Time frame: Week 16 to Week 24
Total Number of New or Newly Enlarging T2 Hyperintense Lesions From Week 64 to Week 72
T2 hyperintense lesions were measured by MRI brain scans.
Time frame: Week 64 to Week 72
Average Annualized Relapse Rate (ARR)
Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Investigator. New or recurrent neurologic symptoms that evolved gradually over months were considered disability progression, not an acute relapse, and were not treated with steroids. The ARR was calculated as the total number of relapses that occurred during the previous 12 months and during the 120 weeks on treatment for participants in Study 109MS202 that continued into Study 109MS311, divided by the total number of person-years followed prior to the study and by the total number of person-years followed during the study, respectively.
Time frame: Baseline to Week 96
Percentage of Participants Experiencing One or More Relapses
Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Investigator. New or recurrent neurologic symptoms that evolved gradually over months were considered disability progression, not an acute relapse, and were not treated with steroids.
Time frame: Baseline to Week 96
Change From Baseline in the Degree of Disability
The Expanded Disability Status Scale (EDSS) measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
Time frame: Baseline to Week 96
Number of Participants Experiencing Disability Progression
Measured by at least a 1.0-point increase on the EDSS from baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from baseline EDSS = 0 that is sustained for 24 weeks.
Time frame: Baseline to Week 96
| Milestone | Dimethyl Fumarate |
|---|---|
| Started | 20 |
| Completed | 17 |
| Not completed | 3 |
| Withdrew: Other | 1 |
| Withdrew: Investigator decision | 2 |
An AE is any untoward medical occurrence that does not necessarily have a causal relationship with treatment. An SAE is any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.
| participants | Dimethyl Fumarate |
|---|---|
| AE | 18 |
| SAE | 2 |
An AE is any untoward medical occurrence that does not necessarily have a causal relationship with treatment.
| participants | Dimethyl Fumarate |
|---|---|
| Number of Participants Discontinuing Treatment Due to an Adverse Event | 0 |
T2 hyperintense lesions were measured by MRI brain scans.
| Participants | Dimethyl Fumarate |
|---|---|
| 0 lesions | 12 |
| 1 lesion | 2 |
| 2 lesions | 1 |
| 3 lesions | 1 |
| 4 lesions | 0 |
| 5 or more lesions | 1 |
T2 hyperintense lesions were measured by MRI brain scans.
| Participants | Dimethyl Fumarate |
|---|---|
| 0 lesions | 8 |
| 1 lesion | 1 |
| 2 lesions | 1 |
| 3 lesions | 0 |
| 4 lesions | 0 |
| 5 or more lesions | 0 |
Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Investigator. New or recurrent neurologic symptoms that evolved gradually over months were considered disability progression, not an acute relapse, and were not treated with steroids. The ARR was calculated as the total number of relapses that occurred during the previous 12 months and during the 120 weeks on treatment for participants in Study 109MS202 that continued into Study 109MS311, divided by the total number of person-years followed prior to the study and by the total number of person-years followed during the study, respectively.
| relapses per person-years | Dimethyl Fumarate |
|---|---|
| Average Annualized Relapse Rate (ARR) | 0.1 |
Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Investigator. New or recurrent neurologic symptoms that evolved gradually over months were considered disability progression, not an acute relapse, and were not treated with steroids.
| percentage of participants | Dimethyl Fumarate |
|---|---|
| Percentage of Participants Experiencing One or More Relapses | 10 |
The Expanded Disability Status Scale (EDSS) measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
| score on a scale | Dimethyl Fumarate |
|---|---|
| Baseline | 1.00 ± 1.026 |
| Change from Baseline at Week 12 | 0.15 ± 0.718 |
| Change from Baseline at Week 24 | 0.29 ± 0.508 |
| Change from Baseline at Week 36 | 0.27 ± 0.832 |
| Change from Baseline at Week 48 | 0.50 ± 0.791 |
| Change from Baseline at Week 72 | 0.71 ± 1.010 |
| Change from Baseline at Week 96 | 0.21 ± 0.964 |
Measured by at least a 1.0-point increase on the EDSS from baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from baseline EDSS = 0 that is sustained for 24 weeks.
| Participants | Dimethyl Fumarate |
|---|---|
| Number of Participants Experiencing Disability Progression | 3 |
Collected over Baseline to Week 96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BG00012 | 0/20 (0%) | 2/20 (10%) | 18/20 (90%) |
| Event | BG00012 |
|---|---|
| Abdominal painGastrointestinal disorders | 1/20 |
| Multiple sclerosis relapseNervous system disorders | 1/20 |
| Event | BG00012 |
|---|---|
| FlushingVascular disorders | 5/20 |
| Multiple sclerosis relapseNervous system disorders | 4/20 |
| Abdominal painGastrointestinal disorders | 3/20 |
| Upper respiratory tract infectionInfections and infestations | 3/20 |
| Viral upper respiratory tract infectionInfections and infestations | 3/20 |
| HeadacheNervous system disorders | 3/20 |
| DysmenorrhoeaReproductive system and breast disorders | 3/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/20 |
| VertigoEar and labyrinth disorders | 2/20 |
| Abdominal pain upperGastrointestinal disorders | 2/20 |
| Age, Categorical(Participants) | Dimethyl Fumarate |
|---|---|
| <=18 years | 14 |
| Between 18 and 65 years | 6 |
| >=65 years | 0 |
| Age, Continuous(years) | Dimethyl Fumarate |
|---|---|
| Mean | 16.7 ± 1.31 |
| Sex: Female, Male(Participants) | Dimethyl Fumarate |
|---|---|
| Female | 13 |
| Male | 7 |
| Race/Ethnicity, Customized(participants) | Dimethyl Fumarate |
|---|---|
| Asian | 1 |
| Black or African American | 0 |
| White | 5 |
| Not Reported Due to Confidentiality Regulations | 13 |
| Other | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2016 to primary completion in Sep 2018, 31 months.
Results were first posted in Nov 2019, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 31 months is below that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →